Michelle Harkins is a Respiratory physician affiliated with University of New Mexico. OpenAlex indexes 64 publications with 3,201 citations (h-index 23).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
72.9%Corticosteroid31.4%Symbicort55%Fluticasone Propionate17%Breo Ellipta13%Dulera8%Flovent Hfa8%Part D<11 patientsbeta2-Adrenergic Agonist20.7%Albuterol Sulfate Hfa75%Ventolin Hfa25%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
15.5%Corticosteroid11.4%Prednisone100%Part D≥27 patientsProton pump inhibitor4.1%Omeprazole100%Part D<11 patientsDermatology
11.6%Interleukin-4 Receptor alpha Antagonist9%Dupixent Pen100%Part D<11 patientsCorticosteroid2.6%Methylprednisolone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2000–2004 per NIH RePORTER. The latest:
- Mentored Patient-Oriented Research Career Development Aw
University of New Mexico
FY2004$127,440K23RR016079 - Mentored Patient-Oriented Research Career Development Aw
University of New Mexico
FY2003$127,440K23RR016079 - Mentored Patient-Oriented Research Career Development Aw
University of New Mexico
FY2002$127,440K23RR016079
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The circulating renin-angiotensin system and mortality among patients hospitalized for COVID-19: a mechanistic substudy of the ACTIV-4 Host Tissue trials
American Journal of Physiology-Lung Cellular and Molecular Physiology
2025 - Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study
Clinical Microbiology and Infection
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Mauricio Tohen, MD, DRPH, MBA
University of New Mexico
Howard Yonas, MD
University of New Mexico
Rhoshel Lenroot, MD
University of New Mexico
Mark Unruh, MD
University of New Mexico
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”